162 related articles for article (PubMed ID: 4077148)
1. H-2 class I antigen expression on mouse teratocarcinoma cell lines.
Démant P; Oudshoorn-Snoek M
Immunogenetics; 1985; 22(6):543-52. PubMed ID: 4077148
[TBL] [Abstract][Full Text] [Related]
2. Mice coisogenically immunized against H-2 class I antigens on transfected L cells reject transplanted embryonal carcinoma cells.
Moser AR; Johnson LL; Dove WF
Immunogenetics; 1985; 22(6):533-41. PubMed ID: 4077147
[TBL] [Abstract][Full Text] [Related]
3. Tumor allograft rejection is mainly mediated by CD8+ cytotoxic T lymphocytes stimulated with class I alloantigens in cooperation with CD4+ helper T cells recognizing class II alloantigens.
Tomita Y; Mayumi H; Eto M; Nomoto K
J Immunol; 1990 Mar; 144(6):2425-35. PubMed ID: 1968930
[TBL] [Abstract][Full Text] [Related]
4. Multiple splenic lymphoid cell subpopulations regulate H-2 antigen expression on teratocarcinoma cells in vivo.
Ostrand-Rosenberg S; Cohn AL; Sandoz JW
J Immunol; 1983 Jun; 130(6):2969-73. PubMed ID: 6133895
[TBL] [Abstract][Full Text] [Related]
5. Transfection and expression of syngeneic H-2 genes does not reduce malignancy of H-2 negative teratocarcinoma cells in the autologous host.
Ostrand-Rosenberg S; Cole GA; Nishimura MI; Clements VK
Cell Immunol; 1990 Jun; 128(1):152-64. PubMed ID: 2344619
[TBL] [Abstract][Full Text] [Related]
6. Involvement of the K and I regions of the H-2 complex in resistance to hemopoietic allografts.
Drizlikh G; Schmidt-Sole J; Yankelevich B
J Exp Med; 1984 Apr; 159(4):1070-82. PubMed ID: 6142918
[TBL] [Abstract][Full Text] [Related]
7. Induction of class I major histocompatibility complex antigens in human teratocarcinoma cells by interferon without induction of differentiation, growth inhibition, or resistance to viral infection.
Andrews PW; Trinchieri G; Perussia B; Baglioni C
Cancer Res; 1987 Feb; 47(3):740-6. PubMed ID: 3026615
[TBL] [Abstract][Full Text] [Related]
8. Natural killer cells recognize common antigenic motifs shared by H-2Dd, H-2Ld and possibly H-2Dr molecules expressed on bone marrow cells.
Yu YY; Forman J; Aldrich C; Blazar B; Flaherty L; Kumar V; Bennett M
Int Immunol; 1994 Sep; 6(9):1297-306. PubMed ID: 7529556
[TBL] [Abstract][Full Text] [Related]
9. Cytotoxic T lymphocyte response to minor H-43a alloantigen in H-43b mice. Privileged H-2Kb restriction to the response is not due to immunodominance or epistatic effect but due to Ir gene function of H-2Kb itself.
Hino T; Ishikawa H; Saito K
J Immunol; 1988 Jan; 140(1):44-51. PubMed ID: 3121741
[TBL] [Abstract][Full Text] [Related]
10. Establishment of a pluripotent embryonal carcinoma cell line not expressing SSEA-1 and ECMA-7 phenotypes.
Gregorová S; Loudová M; Dohnal K; Nosek J; Forejt J
Cell Differ; 1984 Dec; 15(2-4):87-92. PubMed ID: 6152581
[TBL] [Abstract][Full Text] [Related]
11. Immunogenicity of the mutated H-2Kbm1 antigen(s). Test of thyroid graft rejection between B6.C-H-2bm1 and C57BL/6 mice following reciprocal immunization with normal versus malignant cells.
Isakov N; Segal S
Immunobiology; 1983 Dec; 165(5):485-99. PubMed ID: 6363278
[TBL] [Abstract][Full Text] [Related]
12. Expression of hemopoietic histocompatibility antigens on H-2-loss variants of F1 hybrid lymphoma cells: evidence consistent with trans gene regulation.
Rembecki RM; Bennett M; Kumar V; Potter TA
J Immunol; 1987 Apr; 138(8):2734-8. PubMed ID: 3549904
[TBL] [Abstract][Full Text] [Related]
13. A pluripotent human stem-cell clone isolated from the TERA-2 teratocarcinoma line lacks antigens SSEA-3 and SSEA-4 in vitro, but expresses these antigens when grown as a xenograft tumor.
Andrews PW; Damjanov I; Simon D; Dignazio M
Differentiation; 1985; 29(2):127-35. PubMed ID: 2412924
[TBL] [Abstract][Full Text] [Related]
14. Transfection of major histocompatibility complex class I and class II genes causes tumour rejection.
Ostrand-Rosenberg S; Clements VK; Thakur A; Cole GA
J Immunogenet; 1989; 16(4-5):343-9. PubMed ID: 2639907
[TBL] [Abstract][Full Text] [Related]
15. Acute rejection of murine bone marrow allografts by natural killer cells and T cells. Differences in kinetics and target antigens recognized.
Murphy WJ; Kumar V; Bennett M
J Exp Med; 1987 Nov; 166(5):1499-509. PubMed ID: 3316472
[TBL] [Abstract][Full Text] [Related]
16. The expression of MHC antigens by human teratocarcinoma derived cell lines.
Andrews PW; Bronson DL; Wiles MV; Goodfellow PN
Tissue Antigens; 1981 May; 17(5):493-500. PubMed ID: 7199768
[TBL] [Abstract][Full Text] [Related]
17. Modulation of F1 cytotoxic potentials by graft-vs-host reaction. Cooperative non-H-2- and H-2D region-gene control of F1 natural resistance to graft-vs-host reaction-associated immunosuppression.
Ishikawa H; Saito K; Kubota E
J Immunol; 1989 Mar; 142(5):1495-9. PubMed ID: 2918225
[TBL] [Abstract][Full Text] [Related]
18. [Experimental teratocarcinoma in mice: a model system for the study of the relationship between cellular surface antigens and embryonic differentiation].
Gachelin G
Bull Cancer; 1976; 63(1):95-110. PubMed ID: 62594
[TBL] [Abstract][Full Text] [Related]
19. Antigenicity of passively acquired major histocompatibility antigens on T cells.
Swartz TJ; Evavold B; Suzuki H; Yokoyama A; Quintans J
Transplantation; 1988 Jul; 46(1):137-43. PubMed ID: 3260698
[TBL] [Abstract][Full Text] [Related]
20. Strong teratocarcinoma transplantation loci, Gt-1 and Gt-2, flank H-2.
Shedlovsky A; Clipson LJ; VandeBerg JL; Dove WF
Immunogenetics; 1981; 13(5):413-9. PubMed ID: 7298086
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
